Andrew Kramar

发表

Assessment of health status over time by Prevalence and Weighted Prevalence functions: Interface in R

Bastien Cabarrou, Jean-Marie Boher, Thomas Filleron, 2015, Comput. Methods Programs Biomed..

Designing group sequential randomized clinical trials with time to event end points using a R function

Thomas Filleron, Andrew Kramar, Jocelyn Gal, 2012, Comput. Methods Programs Biomed..

Analysis of survival adjusted for quality of life using the Q-TWiST function: Interface in R

Thomas Filleron, Alain Duhamel, Anaïs Jouin, 2016, Comput. Methods Programs Biomed..

SAE: An R package for early stopping rules in clinical trials

Andrew Kramar, C. Bascoul-Mollevi, Agnès Laplanche, 2011, Comput. Methods Programs Biomed..

An R function to non-parametric and piecewise analysis of competing risks survival data

Jean-Marie Boher, Thomas Filleron, Andrew Kramar, 2010, Comput. Methods Programs Biomed..

mROC: a computer program for combining tumour markers in predicting disease states

Benjamin Reiser, Andrew Kramar, David Faraggi, 2001, Comput. Methods Programs Biomed..

Multidimensionality of microarrays: Statistical challenges and (im)possible solutions

Stefan Michiels, Andrew Kramar, Serge Koscielny, 2011, Molecular oncology.

np1: A computer program for dose escalation strategies in phase I clinical trials

Xavier Paoletti, Andrew Kramar, Nadine Houédé, 2007, Comput. Methods Programs Biomed..

Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.

Thomas Filleron, Murielle Mauer, Simone Mathoulin-Pélissier, 2013, European journal of cancer.

Early Stopping Rules in Clinical Trials Based on Sequential Monitoring of Serious Adverse Events

Andrew Kramar, C Bascoul-Mollevi, 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

Progesterone Receptor Quantification as a Strong Prognostic Determinant in Postmenopausal Breast Cancer Women under Tamoxifen Therapy

Andrew Kramar, Pierre-Jean Lamy, Philippe Rouanet, 2002, Breast Cancer Research and Treatment.

Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial☆

Sébastien Clippe, Christophe Hennequin, André Pèlegrin, 2015, EBioMedicine.

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

Andrew Kramar, Caroline Bascoul-Mollevi, Christophe Massard, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.

Franck Molina, Andrew Kramar, Pierre Martineau, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunohistochemical Assessment of the Peripheral Benzodiazepine Receptor in Breast Cancer and Its Relationship with Survival

Andrew Kramar, Pierre Casellas, S. Galiègue, 2004, Clinical Cancer Research.

International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

Richard Sylvester, Andrew Kramar, Madhu Mazumdar, 1997 .

Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials

Peter F Thall, Xavier Paoletti, Andrew Kramar, 2010, Biometrics.